Visterra is a clinical-stage biotechnology company that develops novel therapies to treat patients with kidney diseases and other hard-to-treat diseases. The company's proprietary platform technology, called Hierotope, enables the design of precision antibody-based therapies that target disease-causing proteins. Visterra's lead product candidate, VIS410, is a monoclonal antibody that targets influenza A, including pandemic strains and drug-resistant strains. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.